Testing effectiveness (Phase 2)WithdrawnNCT04109690
What this trial is testing
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Who this might be right for
MDS
Yale University
Showing 20 of 0 results